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Well-diﬀerentiated thyroid cancers (WDTCs) are generally indolent cancers that are associated with a low mortality. Although
the incidence of these tumors is increasing, there has not been an associated increase in the mortality rates. As we gain a greater
understanding and more experience with these good prognosis cancers, the way in which we treat these tumors is evolving. The
deﬁnition of persistent or recurrent disease has seen a shift from being a clinical and/or radiological diagnosis to now one based on
a biochemical blood marker, thyroglobulin. Central lymph node metastases are a very common problem in WDTC, being present
in up to 90% of patients. The optimal surgical management of the central lymph node compartment remains a hotly debated
topic. This paper identiﬁes these controversies and presents available data surrounding these issues. Biochemical tumor markers
are gaining wider use in practice and in time hopefully provide more speciﬁc information with which surgical decision-making
can be based. A summary of the clinically available markers is presented.
1.Introduction
Well-diﬀerentiated thyroid cancers (WDTCs) are the most
common endocrine malignancy. The American Cancer Soci-
ety estimates a total of 44670 new cases of thyroid cancers
to be diagnosed in 2010 and 1690 deaths related to thyroid
cancer [1]. The incidence of thyroid cancer has been steadily
increasing over the past three decades [2]. This increase is
thought to represent the earlier detection of subclinical dis-
ease due to the increased use of oﬃce-based ultrasound and
ultrasound-guided ﬁne-needle aspiration biopsy. Despite
this, the mortality rates for thyroid cancer have remained
relatively stable [3]. WDTCs are generally indolent tumors
associated with low morbidity and mortality. Although 30-
year disease-speciﬁc survival rates can exceed 95%, there is
a subset of patients with metastatic disease where the 5-year
survival can be low as 56% [4].
The management of thyroid cancer has evolved over
the past decades due to an increased understanding in the
pathophysiology of these tumors, analysis of epidemiological
data, and the utilization of newer diagnostic tools. With
the passage of time, more evidence and thus data, albeit
predominately retrospective in nature, is available to assist in
directing decision making. The focus now is moving towards
minimizing morbidity rather than curing patients of this
good prognosis disease.
This paper aims to examine the changes in deﬁnition of
persistent/recurrent disease with a focus on the controversies
surrounding prophylactic central lymph node dissection. In
addition, it will look at some of the emerging biochemical
markers that present exciting future possibilities in the
management of DTC.
2. Recurrent Well-Differentiated
Thyroid Cancer
The goals of initial therapy of WDTC are to remove the
primary tumor, extracapsular disease, and involved lymph2 Journal of Oncology
nodes [5]. This is ideally achieved with minimal morbidity
to the patient. Total thyroidectomy has been shown to
result in lower recurrence rates and improved survival for
papillary thyroid cancers greater than or equal to 1.0cm [6].
Utilizing the SEERS database, Bilimoria et al. were the ﬁrst
to demonstrate that tumors greater than or equal to 1.0cm
had a 15% higher risk of recurrence if lobectomy alone
was performed. Subsequent studies have supported this data
[7, 8].
Following surgery, it is helpful to stage patients
according to the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) classi-
ﬁcation system as this allows for prognostication of indi-
vidual patients with WDTC and decision making regarding
adjuvant treatment, in addition to follow up [5]. The
AJCC/UICC classiﬁcation system stages patients based on
tumor size, lymph node involvement, and the presence
or absence of distant metastases. This system allows for
consistent and accurate communication between health
professionals in addition to comparing similar groups of
patients in clinical studies. However, thyroid cancers behave
diﬀerently to other tumors that utilize TNM staging for
mortality risk, as seen in the unique age diﬀerentiation,
where patients less than 45 years of age are never classiﬁed
as being stage III or above. Most patients with WDTC
have an excellent disease-speciﬁc survival, and the main
concern is related to recurrence, which the TNM staging
system does not take into consideration. Consequently, the
ATA has developed risk stratiﬁcation for recurrence [5].
Factors that are associated with tumor recurrence including
macroscopic residual tumor, aggressive histology (e.g., tall
cell variant, insular cell carcinoma), tumor invasion into
locoregional structures, and distant metastasis are taken into
consideration [9]( Table 1). Early validation of the ATA
recurrence risk stratiﬁcation recommendations is promising
[10].
There has been a paradigm change in the deﬁnition of
recurrence from clinically palpable and/or iodine avid dis-
ease to a biochemically detectable recurrence [5]( Table 2).
Traditionally, disease recurrence was detected on iodine
I131 scanning [11]. Typically, I131 is given approximately
4–6 weeks postsurgery as a diagnostic whole body scan
(DxWBS). Better results are achieved when there is little or
no residual thyroid tissue, in the presence of thyrotropin
(TSH) stimulation and higher doses of iodine [11, 12]. A
major advantage of DxWBS is its ability to identify distant
metastatic disease.
Today, serum thyroglobulin (Tg) and high-resolution
ultrasound (US) are the modalities used for tumor surveil-
lance [13]. Detectable or rising Tg levels following total
thyroidectomy and I131 ablation indicate persistent or recur-
rent disease. Recognizing that thyroid hormone can suppress
Tg levels, TSH-stimulated Tg either with thyroid hormonal
withdrawal or recombinant TSH (rhTSH) is required for
follow-up surveillance. It is important to also measure Tg
antibody (TgAB) as the presence of this interferes with
Tg measurements by binding to Tg thereby causing an
underestimation of serum Tg levels. TgAB is present in up
to 25% of patients diagnosed with DTC compared to 10%
of the general population [14]. The measurements of TgAB
itself may be a surrogate marker for persistent or recurrent
disease. In one study that looked at TgAB levels in patients
who had undergone remnant ablation with undetectable Tg,
22.6% of these patients showed positive TgAB and 49.0% of
these were conﬁrmed with recurrence [15].
Head and neck ultrasonography (US) is a ﬁrst line
imaging modality in the investigation of recurrent thyroid
disease. The main advantages of US include no ionizing
radiation, no known side eﬀects, and easy accessibility. As
it does not rely on iodine uptake, it can identify small
recurrent disease in the neck regardless of Tg measurements
and WBS results. US is usually directed at ascertaining
the presence of thyroid bed recurrences and/or cervical
lymph node metastases. US is operator-dependent and
relies on the experience of the sonographer to diﬀerentiate
between normal and diseased lymph nodes. Nonetheless,
there are features that are associated with pathological
lymphadenopathy. These include the size of the lymph node
(malignant nodes generally being larger than those that are
benign) and the shape (ﬂat is usually benign and round
more likely malignant). Other features more commonly
associated with malignancy are hypoechoic and the presence
of microcalciﬁcations [11]. As with thyroid nodules, when
considered in combination, the presence of these features
raises concern. The additional use of US-guided ﬁne-needle
aspiration biopsy (FNAB) of any suspicious lymph nodes
shouldclarifywhetheralymphnodeismalignantornot.The
disadvantages of US include the user dependency and the
limited anatomical exposure, for example, the retropharynx,
paravertebral, and retrotracheal space. The superiority of
recombinant stimulated TSH (rhTSH) Tg combined with
US in detecting persisting disease has been demonstrated
by Pacini et al. [16]. They were able to show that rhTSH-
stimulated Tg alone had a diagnostic sensitivity of 85%
for detecting active disease and a negative predictive value
(NPV) of 98.2%. When US was added, the sensitivity
increased to 96.3% with a NPV of 99.5%. rhTSH-stimulated
WBS had a sensitivity of only 21% and a NPV of 89%.
3. Management of the Central Lymph
Node Compartment
Cervical lymph node metastases are common and are
reported to be present in 20–90% of patients with WDTC
[8, 17–21]. The risk of regional recurrence is higher in
patients with lymph node metastases, especially in those
with more than 10 involved nodes and with extracapsular
extension [21]. The presence of lymph node metastasis has
also been shown to carry a poorer prognosis [22].
The cervical lymph node compartments are divided into
levels I through VI. These are grouped into central and
lateral compartments. The central compartment or Level
VI is bounded superiorly by the hyoid bone, laterally by
the carotid arteries, and posteriorly by the deep layer of
the deep cervical fascia [23]. This level includes lymph
nodes from the prelaryngeal, pretracheal, and right and left
paratracheal lymph nodes. Surgery for lymph node diseaseJournal of Oncology 3
Table 1: ATA risk stratiﬁcation for recurrent disease.
Low risk Intermediate risk High risk
All the following are present
(i) No local or distant metastases
(ii) All macroscopic tumor has been resected
(iii) No invasion of loco-regional tissues
(iv) Tumor does not have aggressive histology (e.g., tall
cell, insular, columnar cell carcinoma, Hurthle cell
carcinoma, follicular thyroid cancer)
(v) No vascular invasion
(vi) No I131 uptake outside the thyroid bed, if done
Any of the following is present
(i) Microscopic invasion into the
perithyroidal soft tissues
(ii) Cervical lymph node metastases or
31-I uptake outside the thyroid bed on
the post-treatment scan done after
thyroid remnant ablation
(iii) Tumor with aggressive histology or
vascular invasion (e.g., tall cell, insular,
columnar cell carcinoma, Hurthle cell
carcinoma, follicular thyroid cancer)
Any of the following is present
(i) Macroscopic tumor invasion
(ii) Gross residual tumor
(iii) Distant metastases
Table 2: ATA deﬁnition of disease free status.
(i) No clinical evidence of tumor
(ii) No uptake outside the thyroid bed on I131 scans
(iii) No ultrasound evidence of tumor
(iv) Undetectable serum Tg during suppression and TSH stimula-
tion in the absence of TgAB
maybeconsideredtherapeuticorprophylactic.Atherapeutic
dissection occurs when cervical lymph nodes are removed
after they have been demonstrated to contain metastatic
disease based on examination ﬁndings, imaging, cytology, or
intraoperative assessment. Prophylactic dissection of lymph
nodes occurs when there is no evidence of metastatic disease
pre- or intraoperatively. Dissection of cervical lymph nodes,
whether prophylactic or therapeutic, is performed as a com-
partment en-bloc resection, with removal of all lymphatic
tissue rather than isolated lymphadenectomy (berry picking)
as this has been shown to lower rates of persistent and
recurrent disease and possibly mortality [5, 24].
There is general consensus that clinically involved
lymph nodes should be resected, that is, a therapeutic
compartment-orientated dissection, to minimize the risk of
recurrence [24, 25] and possibly mortality [17]. In contrast,
there is considerable controversy concerning the optimal
management of the central lymph node compartment [26–
29] and whether a prophylactic central lymph node dissec-
tion (PCLND) should be performed in patients with PTC.
The reason for much of this controversy is related to the
lack of large randomized, prospective studies in addressing
this issue. The diﬃculty lays with the altered deﬁnition of
recurrence in WDTC. Serum Tg levels and high-resolution
USs are more likely to detect occult disease. Since lymph
node micrometastases are common in PTC, it is conceivable
that leaving occult disease in the central compartment would
result in a biochemical diagnosis of persistent/recurrent
disease. As such, there is a rationale for surgically removing
the ﬁrst drainage basin in a clinically negative neck. Yet,
the clinical signiﬁcance of doing a PCLND has yet to be
established. The majority of evidence on which decisions
are made are based on nonrandomized, retrospective cohort
studies or case series [30]. The information provided in these
studies are also disparate in relation to deﬁnitions of central
lymph node classiﬁcation, descriptions of therapeutic versus
prophylactic dissections, and whether or not postoperative
treatmentwithradioactiveiodine(RAI)treatmentwasgiven.
Since WDTC is an indolent disease with an excellent
prognosis, there is no survival data to support the use of
PCLND, as such recurrence rates are the main focus of the
current literature. Micrometastases in PTC are common,
occurring in up to 90% of examined lymph nodes [31].
Cervical lymph node metastases have been shown to be
associated with increased risk of recurrence and morbidity
[22, 32]. The preoperative evaluation of the cervical lymph
nodes in the central compartment using physical exami-
nation alone may miss macroscopic disease in up to 39%
of patients [33]. Preoperative assessment with ultrasound
is also not able to detect cervical lymph node with a
high degree of sensitivity [34]. In a retrospective analysis,
CLND was shown to result in lower postablation Tg levels,
compared to patients who underwent total thyroidectomy
alone [25]. Supporters also contend that reoperation in the
central neck for recurrent disease carries greater morbidity
with increased recurrent laryngeal nerve (RLN) injury
rates and permanent hypoparathyroidism. Yet when CLND
is performed by surgeons experienced in this technique,
complication rates are comparable to those seen in total
thyroidectomy alone. The accepted incidence of permanent
RLN injury and permanent hypoparathyroidism is 1% to
2% for total thyroidectomy alone. These same rates are
achieved by experienced endocrine surgeons performing
total thyroidectomy and CLND [24].
The use of postoperative RAI has been recommended
to reduce recurrence rates and cause speciﬁc mortality [5].
The indication for use of postsurgical RAI for T1 tumors
is dependent of lymph node status. PCLND allows lymph
nodes to be pathologically assessed. One study was able to
demonstrate upstaging from N0 to N1, and the indication
for RAI was modiﬁed in 30% of patients with T1 tumors
[35]. This upstaging has been demonstrated in other studies
[18]. In centers that selectively use RAI in low risk patients,
PCLND could also potentially decrease the need for RAI in
T2 tumors that are proven to be node negative.
Although experienced surgeons have demonstrated sim-
ilar morbidity rates when performing CLND to that of thy-
roidectomy alone, surgeons with limited experience perform
the majority of operations for thyroid cancer in the United4 Journal of Oncology
States. As such, the key argument against the routine use
of PCLND is exposing the patient to unnecessary morbidity
related to the procedure, particularly when evidence exists
that does not support a clinical beneﬁt [36–39]. As part
of a CLND, the RLN is dissected along its length thereby
exposing it to excessive traction and manipulation. Rates of
temporary RLN following CLND range from 0 to 25%, with
permanent rates ranging from 0 to 11.5% [8]. Permanent
hypoparathyroidism exists when vitamin D and/or calcium
replacement is required 6 months following surgery. To
perform a thorough central lymph node clearance, it is
diﬃcult to preserve the inferior parathyroid glands, neces-
sitating autotransplantation. Transient hypoparathyroidism
rates with CLND range from 14 to 60% with the permanent
rates ranging from 0 to 31% [8, 30].
One of the rationales for supporting PCLND relies on
the high rate of micrometastases in CLN and potential for
increased rated of recurrence if left in situ [17]. Yet, the
data to date does not support this. Wada et al. [36] studied
259 patients who underwent thyroidectomy and neck node
dissection for papillary thyroid microcarcinoma (PMC). Of
the 235 patients who underwent a PCLND, 60.9% were
found to have microscopic nodal involvement. However
only 0.43% of these patients developed a recurrence, with
a mean followup of 61.5 months. These patients were
compared with a group of 155 patients who underwent
thyroidectomy for benign disease and were diagnosed with
incidental PMC. This group did not undergo CLND, and
they were found to have a recurrence rate of 0.65% with
a mean followup of 53 months. In addition, Senyurek et
al. [19] reviewed 343 patients with PTC who underwent
total thyroidectomy alone. There were 6 (2%) patients with
central neck recurrences with a mean follow-up period of 9
years. Interestingly, 3 of these patients had tall cell variant of
PTC, 2 had poorly diﬀerentiated tumors, and 1 had diﬀuse
sclerosing subtype of PTC.
Although the mortality rates associated with PTC are
low, recurrence rates are relatively high. This presents one
of the more challenging aspects of managing patients with
this disease. The role of PCLND remains controversial,
with evidence supporting both sides of the argument. It is
important to appreciate that ultimately PTC has a favorable
outcome in the vast majority of cases and minimizing harm
in these patients is of the utmost priority.
4.MolecularMarkers
Molecular markers have provided the most promising
development in the diagnosis of recurrent and/or metastatic
disease. Reverse transcriptase polymerase chain reaction
(RT-PCR) is a method that allows the molecular detection
of tissue or tumor-speciﬁc messenger RNA (mRNA) in the
peripheral blood [40]. Numerous genes have been used in
thyroid cancer and include Tg, thyroid peroxidase (TPO),
thyrotropin or thyroid stimulating hormone (TSH) receptor,
and the sodium/iodide symporter (NIS) [40].
In 1996, Ditkoﬀ et al. [41] were the ﬁrst group to
use qualitative RT-PCR to detect thyroglobulin mRNA (Tg
mRNA) in the peripheral blood. They were able to show
a strong correlation between Tg mRNA and the presence
of recurrent or metastatic disease. Although this paper
provided great hope in the use of Tg mRNA as a molecular
marker,subsequentstudieswerenotassuccessful,withmuch
variability and inconsistency in the results with Tg mRNA
[42, 43].
Milas et al. recently published their ﬁndings following
the introduction of the routine use of thyrotropin receptor
mRNA (TSHR mRNA) at their institution [44]. Since
2001, their group has studied TSHR mRNA as a molecular
marker of thyroid cancer that can be measured from the
peripheral blood. In this publication [44], they reviewed
1095 samples from a recent cohort of patients and compared
them to conclusions derived from a previous analysis of 663
samples. In their institution, TSHR mRNA is used to guide
decision making in patients with an indeterminate FNAB
results and has been previously reported [45]. An algorithm
based on a combination of the TSHR mRNA value, nodule
size, and ultrasound features is used during assessment
of an indeterminate lesion. Patients with an indeterminate
FNAB result or a follicular neoplasm will undergo a total
thyroidectomy as the initial surgical procedure, if they
meet one of the following criteria: (i) TSHR mRNA >
1ng/mcg, (ii) TSHR mRNA undetectable, biopsied thyroid
nodule size ≥ 3.5cm, and presence of one additional
unfavorable US nodule characteristic, or (iii) TSHR mRNA
undetectable,nodulesize<3.5cm,andpresenceof2ormore
additional US features. Unfavorable sonographic features
were deﬁned as irregular or indistinct nodule margins,
hypervascularity within the nodule, microcalciﬁcations or
an abnormal pattern of calciﬁcations, and hypoechogenicity
or solid composition of the nodule [44]. By applying this
algorithm to model clinical treatment in 54 patients with
follicular neoplasms, they were able to show that 28 of
29 (97%) patients with a diagnosis of cancer would have
undergone an appropriate initial total thyroidectomy. Milas
et al. also evaluated the use of TSHRmRNA as a marker of
recurrentdiseaseandinmonitoringofgoiters.Theresultsare
promising but require ongoing surveillance and analysis of
data before any clear conclusions can be drawn. Nonetheless,
the use of TSHRmRNA may prove to be a useful adjunct in
the assessment of patients with thyroid nodules and cancers.
The utility of other molecular marker testing in thyroid
cancer has been recently summarized [46]. The BRAFV600E
mutation has emerged as an important marker for PTC with
high speciﬁcity of 99.8% [46]. In their study, Cantara et al.
demonstrated that BRAF mutations were always associated
with cancer [47]. BRAF mutations have also been associ-
ated with extrathyroidal extension, lymph node metastases,
increased recurrence, and lower survival rates [48–50]. The
future use of BRAF and other forms of genetic testing
on cytology specimens may assist in determining which
patients require more extensive lymph node dissections,
postoperative therapy, and aggressive follow up.
5. Conclusion
The assessment, management, and followup of diﬀerentiated
thyroid cancers continue to evolve as we gain more under-
standing into its behavior. The deﬁnition of recurrence hasJournal of Oncology 5
shifted from the clinical detectable tumor to biochemically
detectabledisease.WhenWDTCrecurs,itismorecommonly
detected by a rising serum Tg level or a small focus seen
only on US, rather than as a palpable mass in the neck
or as uptake on a whole body scan. In the future, more
sensitive markers that are not inﬂuenced by the presence of
TgAB such as an elevated TSHR mRNA level may replace Tg.
As our understanding of these molecular markers advances,
they may deﬁnitively direct our management in determining
which follicular neoplasm is cancerous or which malignant
PTC will have aggressive behavioral characteristics. These
adjuncts may in the future help identify those patients in
whom a prophylactic CLND would be beneﬁcial.
References
[1] A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics,
2010,” CACancerJournalforClinicians,vol.60,no.5,pp.277–
300, 2010.
[2] J .A.SiposandE.L.M azzaferri,“Th yr oidcanc erepidemiology
and prognostic variables,” Clinical Oncology,v o l .2 2 ,n o .6 ,p p .
395–404, 2010.
[3] L. Davies and H. G. Welch, “Increasing incidence of thyroid
cancer in the United States, 1973-2002,” Journal of the
American Medical Association, vol. 295, no. 18, pp. 2164–2167,
2006.
[4] R. M. Tuttle and R. Leboeuf, “Follow up approaches in
thyroid cancer: a risk adapted paradigm,” Endocrinology and
Metabolism Clinics of North America, vol. 37, no. 2, pp. 419–
435, 2008.
[5] D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised
American thyroid association management guidelines for
patients with thyroid nodules and diﬀerentiated thyroid
cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009.
[6] K.Y .Bilimoria,D .J .Bentrem,C.Y .K oetal.,“Extentofsurgery
aﬀects survival for papillary thyroid cancer,” Annals of Surgery,
vol. 246, no. 3, pp. 375–381, 2007.
[ 7 ]I .D .H a y ,C .S .G r a n t ,E .J .B e r g s t r a l he ta l . ,“ U n i l a t e r a lt o t a l
lobectomy: is it suﬃcient surgical treatment for patients with
AMES low-risk papillary thyroid carcinoma?” Surgery, vol.
124, no. 6, pp. 958–966, 1998.
[8] R. S. Sippel and H. Chen, “Controversies in the surgical man-
agement of newly diagnosed and recurrent/residual thyroid
cancer,” Thyroid, vol. 19, no. 12, pp. 1373–1380, 2009.
[9] H. Tala and R. M. Tuttle, “Contemporary post surgical
management of diﬀerentiated thyroid carcinoma,” Clinical
Oncology, vol. 22, no. 6, pp. 419–429, 2010.
[10] R. M. Tuttle, H. Tala, J. Shah et al., “Estimating risk of recur-
renceindiﬀerentiatedthyroidcanceraftertotalthyroidectomy
and radioactive iodine remnant ablation: using response to
therapy variables to modify the initial risk estimates predicted
by the new American thyroid association staging system,”
Thyroid, vol. 20, no. 12, pp. 1341–1349, 2010.
[11] N. Aygun, “Imaging of recurrent thyroid cancer,” Otolaryngo-
logic Clinics of North America, vol. 41, no. 6, pp. 1095–1106,
2008.
[12] J. J. Shin and M. Milas, “Detection of disease recurrence in
diﬀerentiated thyroid cancer,” Minerva Chirurgica, vol. 65, no.
1, pp. 101–116, 2010.
[13] A. Sabet and M. Kim, “Postoperative management of dif-
ferentiated thyroid cancer,” Otolaryngologic Clinics of North
America, vol. 43, no. 2, pp. 329–351, 2010.
[14] C. A. Spencer, M. Takeuchi, M. Kazarosyan et al., “Serum
thyroglobulin autoantibodies: prevalence, inﬂuence on serum
thyroglobulin measurement, and prognostic signiﬁcance in
patients with diﬀerentiated thyroid carcinoma,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 3 ,n o .4 ,p p .
1121–1127, 1998.
[15] J. K. Chung, Y. J. Park, T. Y. Kim et al., “Clinical signiﬁcance of
elevated level of serum antithyroglobulin antibody in patients
with diﬀerentiated thyroid cancer after thyroid ablation,”
Clinical Endocrinology, vol. 57, no. 2, pp. 215–221, 2002.
[16] F. Pacini, E. Molinaro, M. G. Castagna et al., “Recombinant
human thyrotropin-stimulated serum thyroglobulin com-
bined with neck ultrasonography has the highest sensitivity
in monitoring diﬀerentiated thyroid carcinoma,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 8 ,n o .8 ,p p .
3668–3673, 2003.
[17] C. R. McHenry and R. Phitayakorn, “Diﬃcult problems in
thyroid cancer surgery,” Minerva Chirurgica,v o l .6 5 ,n o .1 ,p p .
83–93, 2010.
[ 1 8 ]B .M .S a d o w s k i ,S .K .S n y d e r ,a n dT .C .L a i r m o r e ,“ R o u t i n e
bilateral central lymph node clearance for papillary thyroid
cancer,” Surgery, vol. 146, no. 4, pp. 696–703, 2009.
[19] Y. G. Senyurek, F. Tunca, H. Boztepe, F. Alag¨ ol, T. Terzioglu,
and S. Tezelman, “The long term outcome of papillary
thyroid carcinoma patients without primary central lymph
nodedissection:expectedimprovementofroutinedissection,”
Surgery, vol. 146, no. 6, pp. 1188–1195, 2009.
[20] S. W. Qubain, S. Nakano, M. Baba, S. Takao, and T. Aikou,
“Distribution of lymph node micrometastasis in pN0 well-
diﬀerentiated thyroid carcinoma,” Surgery, vol. 131, no. 3, pp.
249–256, 2002.
[21] S. Leboulleux, C. Rubino, E. Baudin et al., “Prognostic
factors for persistent or recurrent disease of papillary thyroid
carcinoma with neck lymph node metastases and/or tumor
extension beyond the thyroid capsule at initial diagnosis,”
Journal of Clinical Endocrinology and Metabolism, vol. 90, no.
10, pp. 5723–5729, 2005.
[22] C. I. Lundgren, P. Hall, P. W. Dickman, and J. Zedenius,
“Clinically signiﬁcant prognostic factors for diﬀerentiated
thyroid carcinoma: a populationed-based, nested case-control
study,” Cancer, vol. 106, no. 3, pp. 524–531, 2006.
[23] S. E. Carty, D. S. Cooper, G. M. Doherty et al., “Consensus
statementontheterminologyandclassiﬁcationofcentralneck
dissection for thyroid cancer,” Thyroid, vol. 19, no. 11, pp.
1153–1158, 2009.
[24] D.FritzeandG.M.Doherty,“Surgicalmanagementofcervical
lymph nodes in diﬀerentiated thyroid cancer,” Otolaryngologic
Clinics of North America, vol. 43, no. 2, pp. 285–300, 2010.
[25] M. Sywak, L. Cornford, P. Roach, P. Stalberg, S. Sidhu, and
L. Delbridge, “Routine ipsilateral level VI lymphadenectomy
reduces postoperative thyroglobulin levels in papillary thyroid
cancer,” Surgery, vol. 140, no. 6, pp. 1000–1007, 2006.
[26] E. L. Mazzaferri, G. M. Doherty, and D. L. Steward, “The pros
and cons of prophylactic central compartment lymph node
dissection for papillary thyroid carcinoma,” Thyroid, vol. 19,
no. 7, pp. 683–689, 2009.
[27] T. Carling, W. D. Long, and R. Udelsman, “Controversy
surrounding the role for routine central lymph node dissec-
tion for diﬀerentiated thyroid cancer,” Current Opinion in
Oncology, vol. 22, no. 1, pp. 30–34, 2010.
[28] H.C.Davidson,B.J .P ark,andJ .T .Johnson,“P apillaryth yroid
cancer: controversies in the management of neck metastasis,”
Laryngoscope, vol. 118, no. 12, pp. 2161–2165, 2008.6 Journal of Oncology
[29] M. L. White and G. M. Doherty, “Level VI lymph node
dissection for papillary thyroid cancer,” Minerva Chirurgica,
vol. 62, no. 5, pp. 383–393, 2007.
[30] M. L. White, P. G. Gauger, and G. M. Doherty, “Central
l ym p hn o d ed i s s e c t i o ni nd i ﬀerentiated thyroid cancer,” World
Journal of Surgery, vol. 31, no. 5, pp. 895–904, 2007.
[ 3 1 ]F .A r t u r i ,D .R u s s o ,D .G i u ﬀrida et al., “Early diagnosis by
genetic analysis of diﬀerentiated thyroid cancer metastases
in small lymph nodes,” Journal of Clinical Endocrinology and
Metabolism, vol. 82, no. 5, pp. 1638–1641, 1997.
[32] K. C. Loh, F. S. Greenspan, L. Gee, T. R. Miller, and P. P.
B. Yeo, “Pathological tumor-node-metastasis (pTNM) staging
for papillary and follicular thyroid carcinomas: a retrospective
analysis of 700 patients,” Journal of Clinical Endocrinology and
Metabolism, vol. 82, no. 11, pp. 3553–3562, 1997.
[33] M. A. Kouvaraki, S. E. Shapiro, B. D. Fornage et al., “Role of
preoperative ultrasonography in the surgical management of
patients with thyroid cancer,” Surgery, vol. 134, no. 6, pp. 946–
955, 2003.
[34] Y. Ito, T. Jikuzono, T. Higashiyama et al., “Clinical signiﬁcance
of lymph node metastasis of thyroid papillary carcinoma
located in one lobe,” World Journal of Surgery, vol. 30, no. 10,
pp. 1821–1828, 2006.
[35] S. Bonnet, D. Hartl, S. Leboulleux et al., “Prophylactic lymph
node dissection for papillary thyroid cancer less than 2 cm:
implications for radioiodine treatment,” Journal of Clinical
Endocrinology and Metabolism, vol. 94, no. 4, pp. 1162–1167,
2009.
[36] N. Wada, Q. Y. Duh, K. Sugino et al., “Lymph node metastasis
from 259 papillary thyroid microcarcinomas: frequency, pat-
tern of occurrence and recurrence, and optimal strategy for
neck dissection,” Annals of Surgery, vol. 237, no. 3, pp. 399–
407, 2003.
[37] E. Gemsenj¨ ager, A. Perren, B. Seifert, G. Sch¨ uler, I. Schweizer,
and P. U. Heitz, “Lymph node surgery in papillary thyroid
carcinoma,” Journal of the American College of Surgeons, vol.
197, no. 2, pp. 182–190, 2003.
[38] T. Zetoune, X. Keutgen, D. Buitrago et al., “Prophylactic
central neck dissection and local recurrence in papillary
thyroid cancer: a meta-analysis,” Annals of Surgical Oncology,
pp. 1–7, 2010.
[39] J. L. Roh, J. Y. Park, and C. I. Park, “Total thyroidectomy plus
neck dissection in diﬀerentiated papillary thyroid carcinoma
patients: pattern of nodal metastasis, morbidity, recurrence,
and postoperative levels of serum parathyroid hormone,”
Annals of Surgery, vol. 245, no. 4, pp. 604–610, 2007.
[40] M.GuptaandS.Y.Chia,“Circulatingthyroidcancermarkers,”
Current Opinion in Endocrinology, Diabetes and Obesity, vol.
14, no. 5, pp. 383–388, 2007.
[41] B. A. Ditkoﬀ,M .R .M a r v i n ,S .Y e m u le ta l . ,“ D e t e c t i o no f
circulatingthyroidcellsinperipheralblood,” Surgery,vol.120,
no. 6, pp. 959–965, 1996.
[42] R. P. M. Biscolla, J. M. Cerutti, and R. M. B. Maciel, “Detec-
tion of recurrent thyroid cancer by sensitive nested reverse
transcription-polymerase chain reaction of thyroglobulin and
sodium/iodide symporter messenger ribonucleic acid tran-
scripts in peripheral blood,” Journal of Clinical Endocrinology
and Metabolism, vol. 85, no. 10, pp. 3623–3627, 2000.
[43] M. D. Ringel, P. W. Ladenson, and M. A. Levine, “Molec-
ular diagnosis of residual and recurrent thyroid cancer by
ampliﬁcation of thyroglobulin messenger ribonucleic acid
in peripheral blood,” Journal of Clinical Endocrinology and
Metabolism, vol. 83, no. 12, pp. 4435–4442, 1998.
[44] M. Milas, J. Shin, M. Gupta et al., “Circulating thyrotropin
receptor mRNA as a novel marker of thyroid cancer: clinical
applications learned from 1758 samples,” Annals of Surgery,
vol. 252, no. 4, pp. 643–650, 2010.
[45] M. Milas, P. Mazzaglia, S. Y. Chia et al., “The utility of
peripheral thyrotropin mRNA in the diagnosis of follicular
neoplasms and surveillance of thyroid cancers,” Surgery, vol.
141, no. 2, pp. 137–146, 2007.
[46] L. Yip, E. Kebebew, M. Milas et al., “Summary statement:
utility of molecular marker testing in thyroid cancer,” Surgery,
vol. 148, no. 6, pp. 1313–1315, 2010.
[47] S. Cantara, M. Capezzone, S. Marchisotta et al., “Impact of
proto-oncogene mutation detection in cytological specimens
from thyroid nodules improves the diagnostic accuracy of
cytology,” Journal of Clinical Endocrinology and Metabolism,
vol. 95, no. 3, pp. 1365–1369, 2010.
[48] L. Yip, M. N. Nikiforova, S. E. Carty et al., “Optimizing
surgical treatment of papillary thyroid carcinoma associated
with BRAF mutation,” Surgery, vol. 146, no. 6, pp. 1215–1223,
2009.
[49] R. Elisei, C. Ugolini, D. Viola et al., “BRAF(V600E) mutation
and outcome of patients with papillary thyroid carcinoma:
a 15-year median follow-up study,” Journal of Clinical
Endocrinology and Metabolism, vol. 93, no. 10, pp. 3943–3949,
2008.
[50] M. Xing, D. Clark, H. Guan et al., “BRAF mutation testing of
thyroid ﬁne-needle aspiration biopsy specimens for preoper-
ative risk stratiﬁcation in papillary thyroid cancer,” Journal of
Clinical Oncology, vol. 27, no. 18, pp. 2977–2982, 2009.